Vancomycin (VAN) Experience in Physician Office Infusion Centers (POICs)
October 9, 2013
SAN FRANCISCO, CA (October 9, 2013) – A multi-center review of 100 patients receiving Vancomycin was conducted to determine the effectiveness of patient monitoring and the recognition of adverse events in an outpatient setting. Fifty-one of the patients were female with a mean age of fifty-six years. Forty-eight percent of patients had therapy initiated in the infusion center and data was compared to the group receiving Vancomycin following hospital stays. The groups were similar for all parameters with slightly higher trough levels reported during therapy in the hospitalized group. Culture data was available in seventy-five patients with several mixed infections. Predominant pathogens included methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci. Adverse events occurred in eighteen hospitalized patients and ten patients treated only in the POIC, of these blood dyscrasias accounted for the majority. Nephrotoxicity was seen in four patients. Overall Vancomycin clinical treatment success was 82%, with fifty-six cured and twenty-six improved. Data demonstrates a low rate of adverse events, rarely leading to alterations in therapy, even with trough levels between 15-20mg/dl. Vancomycin may be initiated in a POIC and is a safe and effective drug for continued use in this setting. To learn more, click here.
This study was presented at the 2nd annual IDWeek™. For a printed copy of this research poster study, please call 1.866.654.2451 or email firstname.lastname@example.org.
ABOUT HEALIX, INC.
Healix is the national leader in the delivery of parenteral services to medical facilities. The privately-held company is based in Sugar Land, Texas, and offers customizable, turn-key solutions to help healthcare providers offer streamlined infusion therapy and related care.
ABOUT IDWeek 2013
IDWeek 2013 is an annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA) and the Pediatric Infectious Diseases Society (PIDS). With the theme “Advancing Science, Improving Care,” IDWeek features the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases, including HIV, across the lifespan. IDWeek 2013 took place October 2-6 at the Moscone Center in San Francisco, California. For more information, visit www.idweek.org.
Lucinda J. Van Anglen, PharmD